Kaarijärvi, R., Kaljunen, H., Nappi, L., Fazli, L., Kung, S. H. Y., Hartikainen, J. M., . . . Ketola, K. (2024). DPYSL5 is highly expressed in treatment-induced neuroendocrine prostate cancer and promotes lineage plasticity via EZH2/PRC2. Communications Biology, 7(1), . https://doi.org/10.1038/s42003-023-05741-x
Chicago-referens (17:e uppl.)Kaarijärvi, Roosa, et al. "DPYSL5 Is Highly Expressed in Treatment-induced Neuroendocrine Prostate Cancer and Promotes Lineage Plasticity via EZH2/PRC2." Communications Biology 7, no. 1 (2024). https://doi.org/10.1038/s42003-023-05741-x.
MLA-referens (9:e uppl.)Kaarijärvi, Roosa, et al. "DPYSL5 Is Highly Expressed in Treatment-induced Neuroendocrine Prostate Cancer and Promotes Lineage Plasticity via EZH2/PRC2." Communications Biology, vol. 7, no. 1, 2024, https://doi.org/10.1038/s42003-023-05741-x.
